These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27193179)

  • 1. Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
    Poch DS
    BMC Pulm Med; 2016 May; 16(1):82. PubMed ID: 27193179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
    Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
    Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
    Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
    Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
    Valieva ZS; Taran IN; Martynyuk TV; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
    Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry.
    Garcia AR; Blanco I; Ramon L; Pérez-Sagredo J; Guerra-Ramos FJ; Martín-Ontiyuelo C; Tura-Ceide O; Pastor-Pérez F; Escribano-Subías P; Barberà JA
    Respir Res; 2023 Sep; 24(1):223. PubMed ID: 37715261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A focus on riociguat in the treatment of pulmonary arterial hypertension.
    Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
    Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.